HER2/neu may not be an interesting target in biliary cancers: Results of an early phase II Study with Lapatinib

  • Peck J
  • Wei L
  • Zalupski M
 et al. 
  • 12


    Mendeley users who have this article in their library.
  • 23


    Citations of this article.


PURPOSE: Biliary cancers (BCs) respond poorly to chemotherapy. Lapatinib is a dual inhibitor of epidermal growth factor receptor (EGFR) and HER2/neu, both implicated in cholangiocarcinogenesis. This trial was designed to determine the safety and efficacy of lapatinib in BC.

METHODS: A Fleming phase II design with a single stage of 25 patients was used. The dose of lapatinib was 1,500 mg/day administered orally in 28-day cycles. Tumor and blood specimens were analyzed for expression of HER2/neu and EGFR.

RESULTS: Nine patients with BC enrolled in this study. The study was terminated early because of futility. The most common toxicities were nausea and fatigue (78%) and diarrhea (67%). No responses were observed. Of 8 evaluable patients, 4 (50%) had stable disease. Median progression-free survival was 2.6 months (95% CI 1.6-4.4) and median overall survival was 5.1 months (95% CI 2.0-16.5). No somatic mutations in EGFR (exons 18-21) or HER2/neu were found. We did not find evidence of HER2 overexpression.

CONCLUSIONS: Lapatinib is well tolerated but failed to show activity as a single agent in treating patients with BC. Despite the small patient population, our study is consistent with previous findings, suggesting that targeting HER2/neu does not appear to be an effective therapy for BC.

Author-supplied keywords

  • Biliary cancer
  • Epidermal growth factor receptor
  • HER2/neu
  • Lapatinib

Get free article suggestions today

Mendeley saves you time finding and organizing research

Sign up here
Already have an account ?Sign in

Find this document


  • Joshua Peck

  • Lai Wei

  • Mark Zalupski

  • Bert O'Neil

  • Miguel Villalona Calero

  • Tanios Bekaii-Saab

Cite this document

Choose a citation style from the tabs below

Save time finding and organizing research with Mendeley

Sign up for free